IonField Systems Signs Beta Program Agreement with AstraZeneca for the PlasmaKnife

Share Article

The PlasmaKnife changes the single use disposal paradigm for microplates and AstraZeneca’s adoption demonstrates their leadership in the Life Science Market.

IonField Systems (USA) has entered into a Beta Program Agreement with AstraZeneca plc (UK) so that AstraZeneca gain early experience with IonField Systems’ PlasmaKnife™ microplate treating system. PlasmaKnife™ utilises IonField Systems’ patented plasma treatment allowing the extended reuse of microplates in high throughput screening assays thereby reducing the assay cost, reducing the volume of waste going to landfill or incineration, and also reducing its carbon footprint. In addition, preliminary research has shown that treated plates can improve the surface of new microplates to give more consistency and improve cell adherence. AstraZeneca has consistently invested in innovative technologies of this type to advance science and to reduce environmental impact. The Beta Program will run until the release of the commercially available version of PlasmaKnife™ expected towards the end of 2016.

IonField Systems is the leading supplier of atmospheric pressure plasma surface treatment and cleaning technologies for the pharmaceutical and biotechnology markets. For many years the company has sold the TipCharger™ system, a product that rapidly ionizes organic molecules and permits the extended reuse of plastic pipette tips. In 2016, IonField introduced a higher density format TipCharger™ for 1536 pin tools and the PlasmaKnife™ which uses the same proven plasma technology to restore virtually any microplate, typically for hundreds of reuses. With 8 issued patents and another half dozen patents in the application process, IonField continues to pioneer new breakthroughs and develop products that are best in class. IonField Systems is a US company based in Moorestown, NJ with distribution in major pharmaceutical and biotechnology research markets.

AstraZeneca plc is a global science-led biopharmaceutical company, with a portfolio of innovative medicines for major diseases including cancer, cardiovascular, gastrointestinal, neuroscience, respiratory and inflammation. It is the world’s seventh-largest pharmaceutical company measured by 2012 prescription drug sales and has operations in over 100 countries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Paul Hensley
IonField Systems
+1 (856) 437-0330 Ext: 101
Email >
Visit website